Sign In
Buy ALLR
$1.19
-0.0300 (-2.46%)
At Close: Jul 24, 2026
Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial Financing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Str
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
08:15am, Wednesday, 18'th Feb 2026
Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung Cancer Trial is fully funded by the U.S. Department of Veterans Affairs and is open for enro
This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Cardio Diagnostics (NASDAQ:CDIO)
01:54am, Tuesday, 13'th Jan 2026
Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contr
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
08:00am, Wednesday, 31'st Dec 2025
TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing s
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 21.9% in December
05:14am, Tuesday, 30'th Dec 2025
Allarity Therapeutics, Inc. (NASDAQ: ALLR - Get Free Report) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totaling 265,860 share
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
09:00am, Friday, 14'th Nov 2025
Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trial Advanced DRP ® platform throug
- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
08:00am, Wednesday, 17'th Sep 2025
TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing s
Allarity Therapeutics shares pop as ovarian cancer therapy recieves FDA Fast Track Designation
11:47am, Tuesday, 26'th Aug 2025
Allarity Therapeutics (NASDAQ:ALLR) shares more than doubled after the pharmaceutical firm annoucned that its investigational therapy for advanced ovarian cancer, stenoparib, has received Fast Track D
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
08:00am, Tuesday, 26'th Aug 2025
TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing steno
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
04:30pm, Friday, 15'th Aug 2025
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP ® companion diagnostic - S
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
08:00am, Tuesday, 15'th Jul 2025
TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenopa
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
08:00am, Monday, 07'th Jul 2025
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenopar
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
08:00am, Friday, 27'th Jun 2025
TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenopa
